Natalia JANKARASHVILI, Lasha TURKIASHVILI, Sophio KAKHADZE, Maia TOPESHASHVIL, Mariam TCHIABRISHVILI

Neoadjuvant volumetric modulated arc radiochemotherapy with a simultaneous integrated boost technique compared to standard chemoradiation for locally advanced rectal cancer

Background/aim: The present study aimed to examine whether the combination of neoadjuvant volumetric modulated arc radiotherapy(VMAT) using simultaneous integrated boost (SIB-VMAT) techniques and chemotherapy with capecitabine is associated with better clinicaland dosimetric outcomes compared to the standard treatment.Materials and methods: The study included 59 patients with cT2–T4 rectal cancer. In the standard arm, patients (n = 37) were treatedpreoperatively with image-guided VMAT plus capecitabine. In the SIB arm, patients (n = 22) were treated with the SIB-VMAT techniqueplus capecitabine. All patients underwent radical surgical resection after neoadjuvant radiochemotherapy.Results: In the standard arm, cT0N0 was reached in 12 patients (32.4%), primary tumor clinical downstaging was observed in 22 patients(59.5%), and disease stability was achieved in 3 patients (8.1%). In the SIB arm, cT0N0 was reached in 15 patients (68.2%), primary tumorclinical downstaging was observed in 6 patients (27.3%), and disease stability was achieved in 1 patient (4.5%) (P = 0.028). Completepathological response was observed in 11 patients (29.7%) in the standard arm and in 13 patients (59.1%) in the SIB arm (P = 0.026). In theSIB arm mild diarrhea appeared in 59.1%, moderate in 40.9%, and severe in 0% of the cases. In the standard arm mild, moderate, and severediarrhea rates were in 54.1%, 43.2%, and 2.7%, respectively. In the SIB arm mild, moderate, and severe cystitis appeared in 63.6%, 22.7%,and 13.6%, while in the standard group mild cystitis developed in 67.6%, moderate in 24.3%, and severe in 8.1%. Mild, moderate, and severeradiation dermatitis rates were 45.5%, 45.5%, and 9.1% in the SIB group and 40.5%, 48.6%, and 10.8% in the standard group, respectively.Conclusion: The SIB-VMAT technique is effective and safe for irradiating locally advanced rectal cancer. Its effectiveness is expressed inhigher clinical and pathological complete response rates and safety with the same rates of acute toxicity.

PDF

___

1. Trakarnsanga A, Ithimakin S, Weiser MR. Treatment of locally advanced rectal cancer: controversies and questions. World Journal of Gastroenterology 2012; 18 (39): 5521-5532. doi: 10.3748/wjg.v18.i39.5521
2. de Wilt JHW, Vermaas M, Ferenschild FTJ, Verhoef C. Management of locally advanced primary and recurrent rectal cancer. Clinics in Colon and Rectal Surgery 2007; 20 (3): 255- 264. doi: 10.1055/s-2007-984870
3. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. New England Journal of Medicine 2004; 351 (17): 1731-1740. doi: 10.1056/NEJMoa040694
4. Glynne-Jones R, Harrison M. Locally advanced rectal cancer: what is the evidence for induction chemoradiation? Oncologist 2007; 12 (11): 1309-1318. doi: 10.1634/ theoncologist.12-11-1309
5. Voelter V, Zouhair A, Vuilleumier H, Matter M, Bouzourene H et al. CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II. British Journal of Cancer 2006; 95 (6): 710-716. doi: 10.1038/sj.bjc.6603322
6. Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. International Journal of Radiation Oncology, Biology, Physics 2006; 66 (3): 762-771. doi: 10.1016/j. ijrobp.2006.05.063
7. Mok H, Crane CH, Palmer MB, Briere TM, Beddar S et al. Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiation Oncology 2011; 6: 63. doi: 10.1186/1748-717X-6-63
8. Richetti A, Fogliata A, Clivio A, Nicolini G, Pesce G et al. Neoadjuvant chemo-radiation of rectal cancer with volumetric modulated arc therapy: summary of technical and dosimetric features and early clinical experience. Radiation Oncology 2010; 5: 14. doi: 10.1186/1748-717X-5-14
9. Cilla S, Caravatta L, Picardi V, Sabatino D, Macchia G et al. Volumetric modulated arc therapy with simultaneous integrated boost for locally advanced rectal cancer. Clinical Oncology 2012; 24 (4): 261-268. doi: 10.1016/j.clon.2011.07.001
10. Ahnesjo A, Hardemark B, Isacsson U, Montelius A. The IMRT information process e mastering the degrees of freedom in external beam therapy. Physics in Medicine and Biology 2006; 51 (13): 381-402. doi: 10.1088/0031-9155/51/13/R22
11. Movsas B, Diratzouian H, Hanlon A, Cooper H, Freedman G et al. Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer. American Journal of Clinical Oncology 2006; 29 (5): 435-441. doi: 10.1097/01.coc.0000227480.41414.f2
12. Lupattelli M, Matrone F, Gambacorta MA, Osti M, Macchia G et al. Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with capecitabine in locally advanced rectal cancer: short-term results of a multicentric study. Radiation Oncology 2017; 12 (1): 139. doi: 10.1186/s13014-017-0870-4
13. Shang J, Kong W, Wang Y, Ding Z, Yan G et al. VMAT planning study in rectal cancer patients. Radiation Oncology 2014; 9: 219. doi: 10.1186/s13014-014-0219-1
14. Wu H, Jiang F, Yue H, Li S, Zhang Y. A dosimetric evaluation of knowledge-based VMAT planning with simultaneous integrated boosting for rectal cancer patients. Journal of Applied Clinical Medical Physics 2016; 17 (6): 78-85. doi: 10.1120/jacmp.v17i6.6410
15. Sanghera P, Wong DWY, McConkey CC, Geh JI, Hartley A. Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clinical Oncology 2008; 20 (2): 176-183. doi: 10.1016/j.clon.2007.11.013
16. Mohiuddin M, Regine WF, John WJ, Hagihara PF, McGrath PC et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathologic complete response. International Journal of Radiation Oncology, Biology, Physics 2000; 46 (4): 883-888. doi: 10.1016/s0360-3016(99)00486-1
17. Wiltshire KL, Ward IG, Swallow C, Oza AM, Cummings B et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, diseasefree survival, and overall survival. International Journal of Radiation Oncology, Biology, Physics 2006; 64 (3): 709-716. doi: 10.1016/j.ijrobp.2005.08.012
18. Ferenschild FT, Vermaas M, Nuyttens JJ, Graveland WJ, Marinelli AW et al. Value of intraoperative radiotherapy in locally advanced rectal cancer. Diseases of Colon and Rectum 2006; 49 (9): 1257-1265. doi: 10.1007/s10350-006-0651-x
19. Gerard JP, Conroy T, Bonnetain F, Bouché O, Chapet O et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. Journal of Clinical Oncology 2006; 24 (28): 4620- 4625. doi: 10.1200/JCO.2006.06.7629
20. Bosset JF, Collette L, Calais G, Mineur L, Maingon P et al. Chemotherapy with preoperative radiotherapy in rectal cancer. New England Journal of Medicine 2006. 355 (11): 1114- 1123. doi: 10.1056/NEJMoa060829
21. Bosset JF, Calais G, Daban A, Berger C, Radosevic-Jelic L et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. European Journal of Cancer 2004; 40 (2): 219-224. doi: 10.1016/j.ejca.2003.09.032
22. Yerushalmi R, Idelevich E, Dror Y, Stemmer SM, Figer A et al. Preoperative chemoradiation in rectal cancer: retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. Journal of Surgical Oncology 2006; 93 (7): 529- 533. doi: 10.1002/jso.20503
23. Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. International Journal of Radiation Oncology, Biology, Physics 2002; 54 (2): 403-408. doi: 10.1016/s0360- 3016(02)02856-0
24. Rodel C, Liersch T, Hermann RM, Arnold D, Reese T et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. Journal of Clinical Oncology 2007. 25 (1): 110-117. doi: 10.1200/JCO.2006.08.3675
25. Klautke G, Kuchenmeister U, Foitzik T, Ludwig K, Prall F et al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. British Journal of Cancer 2006; 94 (7): 976-981. doi: 10.1038/sj.bjc.6603053
26. Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. Journal of Clinical Oncology 2006; 24 (4): 650-655. doi: 10.1200/JCO.2005.03.6095
27. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. Journal of Clinical Oncology 2006; 24 (4): 668-674. doi: 10.1200/JCO.2005.04.4875
28. Nijkamp J, Haustermans K, Marijnen CAM. What is the Role of IMRT and IGRT in rectal cancer? In: Valentini V, Schmoll HJ, van de Velde CJH (editors). Multidisciplinary Management of Rectal Cancer. Berlin, Germany: Springer; 2012. Pp. 132-133.
29. Ortholan C, Francois E, Thomas O, Benchimol D, Baulieux J et al. Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials. Diseases of Colon and Rectum 2006; 49 (3): 302-310. doi: 10.1007/s10350- 005-0263-x
30. Macchia G, Deodato F, Cilla S, Cammelli S, Guido A et al. Volumetric modulated arc therapy for treatment of solid tumors: current insights. OncoTargets and Therapy 2017; 10: 3755-3772. doi: 10.2147/OTT.S113119